NOVAVAX INC

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

NVAX$10.20-6.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Consolidated Financial Statements

Item 1. Financial Statements

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share information)

	For the Three Months EndedMarch 31,
	2026	2025
Revenue:
Product sales	$42,200	$621,678
Licensing, royalties, and other	97,314	44,977
Total revenue	139,514	666,655
Expenses:
Cost of sales	30,695	14,115
Research and development	95,472	88,937
Selling, general, and administrative	28,777	48,090
Total expenses	154,944	151,142
Income (loss) from operations	(15,430)	515,513
Other income (expense):
Interest expense	(4,901)	(5,723)
Other income, net	11,825	10,056
Income (loss) before income tax expense	(8,506)	519,846
Income tax expense	985	1,200
Net income (loss)	$(9,491)	$518,646
Net income (loss) per share:
Basic	$(0.06)	$3.22
Diluted	$(0.06)	$2.93
Weighted average number of common shares outstanding:
Basic	163,276	161,049
Diluted	163,276	177,625

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

	For the Three Months EndedMarch 31,
	2026	2025
Net income (loss)	$(9,491)	$518,646
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale marketable securities	(1,447)	589
Foreign currency translation adjustment	(5,637)	23,578
Other comprehensive income (loss)	(7,084)	24,167
Comprehensive income (loss)	$(16,575)	$542,813

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.